721 days ago
When I suggested Shield Therapeutics (STX) was a nailed-down short, on the basis that it would face a cash crisis by May, my analysis was met with derision by Bulletin Board Morons. “He does not understand biotech, he does not understand Shield, he’s a failed fund manager, he is ALWAYS wrong, he works in a pizza store, he’s fleeing the UK to Greece to avoid jail”, were some of the more polite comments. It is now May, and the shares are just 17p to sell. So, what next?
1374 days ago
There is no need for anyone else to listen to this podcast. This is a lesson in how to do fundamental analysis of a biotech stock for just one reader, Peter “the ramper” Brailey.
2202 days ago
I was chatting to Dom Frisby this morning ahead of the Sarries evening tomorrow which is the first part of UK Investor (gold tickets only). More on that in the podcast where I also look at UK house prices, Ascent Resources (AST), Immupharma (IMM), investing in biotech, PCGE (PCGE), MySquar (MYSQ) and its new marriage from hell and at Versarien (VRS). Tin hat on after that annoying its deranged fans by daring to ask questions. If you like bearcasts then remember that at UK Investor on April 21 - THIS SATURDAY - one of many highlights will be a live bearcast with myself and Paul Scott. Make sure you book a free ticket HERE using the promotional code WINNIFRITH.
2393 days ago
The real fear Neil Woodford has is redemptions. The sleazey scoops for blow job articles deals in today's Sunday Times cannot hide that. I look at the absurd valuation of Oxford Nanopore, an unlisted biotech Unicorn, puffed in today's paper but also at the cracks now showing despite the glowing piffle in the same paper's write up on Nomates himself
2751 days ago
Yes that is this afternoon's treat and it reminds me of when the Mrs and I went there to get permission to marry. On the markets I look at China Africa Resources (CAL) - what could possibly go wrong? Then I cover Synairgen (SNG) and the risks folks do not understand in biotech, DiamondCorp (DCP), Premier Foods (PFD), Golden Saint Resources (GSR) and what PR genius Steffi has not told you.
2868 days ago
I am back in from the fields where I have been labouring in 40 degree plus heat. Today I offer a few thoughts on Circassia (CIR) and the risks folks just dont seem to appreciate of a) biotech and b) backing stock selections of star fund managers, in this case Neil Woodford - who incidentally is clearly a very talented chap. I look at Gulf Keystone (GKP), XCite Energy (XEL), China Frauds and then in some detail at Blur (BLUR). For further info on its brain dead dickhead of a PR man Dominic Barretto go HERE
2868 days ago
Hats off to veteran journalist Tim Blackstone who called Circassia (CIR) as a short with a £900 million market cap on January 16 this year HERE. Today the shares have crashed by 64% to 98.5p giving it a market cap of just £261 million. Tim Blackstone dared to go up against Neil Woodford with this call as he is the largest shareholder. It looks like another biotech disaster for Woodie.
2899 days ago
Biotech outfit Summitt (SUMM) may have some interesting IP but it is pretty early stage, years away from generating a cent in revenues, other than the odd grant, and it is munching up cash at an alarming rate. Results came out the other day for the year to January 31 2016 and they really do beg the question: when's the placing? Perhaps that is why the shares have slumped from c150p at the start of the year to just 112p today?
2908 days ago
And now for a video from the biotech boss who I have sworn to be nice to, Dr Satu Vainikka of ValiRx (VAL) presenting at UK Investor Show. Enjoy.
2974 days ago
This podcast looks at three men. First is the criminal fraudster and expenses thief Rob Terry and I discuss what sort of trial and what sort of punishment needs to take place and be imposed. Then it is fund manager Neil Woodford and I look at his growing biotech headaches. Finally the greedy pig Richard Chase of Nyota. If you have not yet listened to yesterday's special on this failure of a CEO please do so and send the email I request.
2986 days ago
AIM listed biotech Reneuron (RENE) has today announced that it has completed the move of all of its operations from Surrey to Pencoed, Bridgend, Wales. Hooray...welcome to the most expensive job creation programme in history paid for with YOUR money.
This deal was first announced two years ago and involved the Welsh Assembly handing over a grant of £7.8 million to get the company to move from Surrey, where it employed 25 folks at the time, to the land of the Sheep Shaggers.
You will note that Wales is a net taker
3058 days ago
I start with back news, not good but at least I have a handy tip for dodging passport control. Then it is onto the son of the late Brian Schneider of OEM infamy. He wants you and I to pay far more tax from our legitimate earnings though he has lived a privileged life - and still does - thanks to the proceeds of crime. He is a leading Jeremy Corbyn organiser. Right on Comrades. I look at Petropavlovsk (POG) and the idea of buying shares for the bid. I move onto a new biotech IPO, Levrett. I explain why its a bargepole but also how the coverage of this in the Mail on Sunday (Simon Watkins) shows again the corrupt nexus between certain financial journalists and the PR world with an aim to dupe you, the investor. Then it is onto Jabba The Hutt's Afriag (AFRI) where I follow on from today's bombshell HERE and the follow up HERE by explaining the real problem it - and AIM - now faces.
3145 days ago
Forget all the jam tomorrow garbage from serial cash burning biotech loser ValiRX (VAL) the half year report out this morning is a dog’s dinner. Look at the numbers.
3164 days ago
Shares in much ramped AIM listed biotech Scancell (SCLP) now trade at 28-30.5p valuing it at a stonking £65 million. But the balance sheet is painfully thin and the word is that there is a placing on the way at a big discount.
3213 days ago
Once again IT issues in Greece delay this podcast. I start by explianing why the reaction of Paul Scott and the craven deadwood press to the new national living wage proposed by George Osborne displays 100% economic illiteracy. It is simply a transfer of wealth from business to the State, the poor will gain nothing. Then onto defending David Lenigas and Andrew Bell from some of the sillier comments made by some folk and to explain why flip flop Ben Turney is again wrong on New World Oil & Gas. hats off to Paul Curtis for the silliest remark of the day as I stck the boot into Gulf Keystone and then also to the prep, pump and dump at Beowulf Mining. And finally I have another go at biotech dog ValiRx.
And fear not Champagne Charlie Gibson fans, I had not forgotten about you. Just a reminder of why the Edison analyst is a convicted felon HERE and as a bonus a reminder of how it is not only the poor he screws HERE - and a reminder of why I feel the urge to remind you all HERE
3228 days ago
In today's podcast I relay my experience of Argos, there is always something new in life. Anyhow I now have new headphones so I hope the sound quality is better. Then onto Daniel Stewart, Rob Terry, Imaginatik, Mwana Africa, ValirX, biotech in general, Auhua Clean and IGAS
3245 days ago
In this podcast I ponder the similarities between the two sectors, a few thoughts on following experts like Jim Mellon (biotech) or Malcolm Burne (gold) and wonder what the renaissance of both sectors says about the wider market.
3528 days ago
Never tip Chinese stocks is a golden rule I broker a couple of months ago when tipping shares in Hutchison China MediTech (HCM) at an 870p offer on my Nifty Fifty website. All seemed to be plain sailing until…
4025 days ago
I was one of the founding directors of AIM listed Port Erin Biopharma (PEBI) but it was always the baby of Jim Mellon and I was happy to step down last Spring. Jim is good at picking biotech stocks and so I tipped the shares at a 5.5p offer price before Christmas on the grounds that I reckoned that the NAV of this company was c9.5p at the time – that discount (well over 40%) was too great.
Mellon has delivered the goods.
